AR040781A1 - Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceutica - Google Patents
Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceuticaInfo
- Publication number
- AR040781A1 AR040781A1 AR20030102794A ARP030102794A AR040781A1 AR 040781 A1 AR040781 A1 AR 040781A1 AR 20030102794 A AR20030102794 A AR 20030102794A AR P030102794 A ARP030102794 A AR P030102794A AR 040781 A1 AR040781 A1 AR 040781A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- alkyl
- group
- hydrogen
- haloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000003998 progesterone receptors Human genes 0.000 title abstract 2
- 108090000468 progesterone receptors Proteins 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical group 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000232 haloalkynyl group Chemical group 0.000 abstract 2
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 abstract 1
- 125000004641 (C1-C12) haloalkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 abstract 1
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 1
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 abstract 1
- 208000005171 Dysmenorrhea Diseases 0.000 abstract 1
- 206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
- 201000009273 Endometriosis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010027514 Metrorrhagia Diseases 0.000 abstract 1
- 206010067269 Uterine fibrosis Diseases 0.000 abstract 1
- 239000004015 abortifacient agent Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003433 contraceptive agent Substances 0.000 abstract 1
- 229940124558 contraceptive agent Drugs 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 230000004720 fertilization Effects 0.000 abstract 1
- 125000000262 haloalkenyl group Chemical group 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 201000010260 leiomyoma Diseases 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 230000035935 pregnancy Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41796802P | 2002-10-11 | 2002-10-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040781A1 true AR040781A1 (es) | 2005-04-20 |
Family
ID=31994318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AR20030102794A AR040781A1 (es) | 2002-10-11 | 2003-08-04 | Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceutica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7163946B2 (https=) |
| EP (1) | EP1554283A1 (https=) |
| JP (1) | JP2006504737A (https=) |
| AR (1) | AR040781A1 (https=) |
| AU (1) | AU2003258051A1 (https=) |
| CA (1) | CA2501834A1 (https=) |
| CL (1) | CL2003001545A1 (https=) |
| DE (1) | DE20301728U1 (https=) |
| HK (1) | HK1055059A2 (https=) |
| MX (1) | MXPA05003801A (https=) |
| TW (1) | TW200413384A (https=) |
| WO (1) | WO2004033461A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
| AU2003258050A1 (en) | 2002-10-11 | 2004-05-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| CA2501833A1 (en) | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
| CN112424205B (zh) * | 2018-07-12 | 2023-10-31 | 伊莱利利公司 | 选择性的雌激素受体降解剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635941A (en) | 1969-04-01 | 1972-01-18 | Eastman Kodak Co | Disperse mono azo dyes containing an acylamidotetrahydroquinoline group |
| US3907507A (en) | 1971-04-26 | 1975-09-23 | Heliodoro Monroy Rivera | Novel apparatus for the obtention of substituted 1,2-dihydroquinolines |
| CA2074933C (en) | 1990-11-30 | 2002-12-03 | Masatoshi Chihiro | Thiazole derivatives as active superoxide radical inhibitors |
| JPH04316557A (ja) | 1991-04-16 | 1992-11-06 | Kyorin Pharmaceut Co Ltd | ６−アリール環状アントラニル酸誘導体 |
| US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
| EP1043325B1 (en) | 1994-12-22 | 2004-06-16 | Ligand Pharmaceuticals Incorporated | Steroid receptor modulator compounds and methods |
| US6696459B1 (en) | 1994-12-22 | 2004-02-24 | Ligand Pharmaceuticals Inc. | Steroid receptor modulator compounds and methods |
| US5696130A (en) | 1994-12-22 | 1997-12-09 | Ligand Pharmaceuticals Incorporated | Tricyclic steroid receptor modulator compounds and methods |
| PT918774E (pt) | 1996-06-27 | 2002-05-31 | Ligand Pharm Inc | Compostos moduladores do receptor para androgenio e metodos |
| BR9907788A (pt) * | 1998-02-13 | 2001-10-30 | Abbott Lab | Agentes antiinflamatórios seletivos paraglicocorticóides |
| US6380207B2 (en) | 1998-02-13 | 2002-04-30 | Abbott Laboratories | Glucocortiocoid-selective antiinflammatory agents |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| US6093826A (en) | 1998-06-08 | 2000-07-25 | Ligand Pharmaceuticals Incorporated | Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines |
| DE20301728U1 (de) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen |
| AU2003258050A1 (en) | 2002-10-11 | 2004-05-04 | Ligand Pharmaceuticals Incorporated | 5-cycloalkenyl 5h-chromeno(3,4-f)quinoline derivatives as selective progesterone receptor modulator compounds |
| CA2501833A1 (en) | 2002-10-11 | 2004-04-22 | Ligand Pharmaceuticals Incorporated | 5-(1',1'-cycloalkyl/alkenyl)methylidene 1,2-dihydro-5h-chromeno[3,4-f]quinolines as selective progesterone receptor modulator compounds |
-
2003
- 2003-02-04 DE DE20301728U patent/DE20301728U1/de not_active Expired - Lifetime
- 2003-08-04 AR AR20030102794A patent/AR040781A1/es not_active Application Discontinuation
- 2003-08-04 JP JP2004543233A patent/JP2006504737A/ja active Pending
- 2003-08-04 AU AU2003258051A patent/AU2003258051A1/en not_active Abandoned
- 2003-08-04 EP EP03808052A patent/EP1554283A1/en not_active Withdrawn
- 2003-08-04 TW TW092121283A patent/TW200413384A/zh unknown
- 2003-08-04 HK HK03105598A patent/HK1055059A2/xx not_active IP Right Cessation
- 2003-08-04 CA CA002501834A patent/CA2501834A1/en not_active Abandoned
- 2003-08-04 WO PCT/US2003/024420 patent/WO2004033461A1/en not_active Ceased
- 2003-08-04 CL CL200301545A patent/CL2003001545A1/es unknown
- 2003-08-04 MX MXPA05003801A patent/MXPA05003801A/es unknown
- 2003-10-10 US US10/684,212 patent/US7163946B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2501834A1 (en) | 2004-04-22 |
| CL2003001545A1 (es) | 2005-01-07 |
| HK1055059A2 (en) | 2003-12-05 |
| US20040152717A1 (en) | 2004-08-05 |
| AU2003258051A1 (en) | 2004-05-04 |
| WO2004033461A1 (en) | 2004-04-22 |
| DE20301728U1 (de) | 2004-03-11 |
| MXPA05003801A (es) | 2005-06-08 |
| JP2006504737A (ja) | 2006-02-09 |
| TW200413384A (en) | 2004-08-01 |
| US7163946B2 (en) | 2007-01-16 |
| EP1554283A1 (en) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| PE20090890A1 (es) | Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c | |
| UA72917C2 (en) | Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor | |
| AR041055A1 (es) | Derivados de benzoimidazol utiles como agentes antiproliferativos, composicion farmaceautica en base al compuesto y un procedimiento de preparacion del compuesto | |
| AR046964A1 (es) | Heterociclos azabiciclicos como moduladores de receptor canabinoide, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades relacionadas con trastornos metabolicos y de la alimentacion. | |
| AR043015A1 (es) | Compuestos moduladores de amida derivada de quinolina del receptor vanilloide vr1, composiciones farmaceuticas y veterinarias que los contienen y su uso en el tratamiento de enfermedades afectadas por la modulacion de dichos receptores | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR028985A1 (es) | Compuestos derivados de quinolin-2-ona- sustituidos con heteroarilo utiles como agentes anticancerigenos, procedimiento de tratamiento de enfermedades utilizando dicho compuesto, composicion farmaceutica que lo contiene | |
| UY27322A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| AR052215A1 (es) | 3-aminociclopentancarboxamidas como moduladores de receptores de quimioquinas, su uso en el tratamiento de enfermedades relacionadas y composiciones farmacéuticas que las contienen. | |
| AR078674A1 (es) | Derivados de pirazolo[3, 4-d]pirimidina, un intermediario para su sintesis, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las pi3-quinasas | |
| AR035759A1 (es) | Compuestos acilurea antagonistas de la funcion mpc-1, un procedimiento para su preparacion, composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| MXPA05010859A (es) | Antagonistas mchr1 heterociclicos. | |
| MX2007012936A (es) | Derivados de dihidrobenzofurano y usos de los mismos. | |
| MA26904A1 (fr) | Aminoalkyl 1-lactames substituees et leur utilisation en tant qu'antagonistes du recepteur muscarinique. | |
| AR035153A1 (es) | Derivados de carboxamidas y cetonas de dihidrobenzodioxina | |
| AR034174A1 (es) | Compuestos de benzoxazinona, procedimiento para su preparacion, composiciones farmaceuticas que lo comprenden, procedimiento para la preparacion de tales composiciones, y el uso de dichos compuestos o composiciones en la fabricacion de medicamentos | |
| EA200970704A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ АНТАГОНИСТЫ NK1 РЕЦЕПТОРА И БЛОКАТОРЫ Na КАНАЛОВ | |
| MA26906A1 (fr) | Aminoalkyl 1-lactames substituees et leur utilisation en tant qu'antagonistes du recepteur muscarinique | |
| ATE530182T1 (de) | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen | |
| MXPA05006887A (es) | Derivados de 1-piperidin-4-il-4-pirrolidin-3-il-piperazina sustituidos y su uso como antagonistas de neurocininas. | |
| AR040781A1 (es) | Compuestos 5-sustituidos de 7,9 -difluoruro- 5 h- cromeno [3 ,4-f] quinolina como compuestos moduladores selectivos de receptores de progesterona y composicion farmaceutica | |
| AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |